About PLx Pharma
PLx Pharma is a company based in Sparta (United States) founded in 2002 by Ron Zimmerman. PLx Pharma has raised $25.27 million across 21 funding rounds from investors including HHS and Aurus. The company has 19 employees as of December 31, 2022. PLx Pharma operates in a competitive market with competitors including Ironwood Pharma, Lyndra, RedHill Biopharma, Alcresta and Seed, among others.
- Headquarter Sparta, United States
- Employees 19 as on 31 Dec, 2022
- Founders Ron Zimmerman
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Plx Pharma, Inc.
-
Annual Revenue
$778.66 K (USD)3793as on Dec 31, 2017
-
Net Profit
-$21.32 M (USD)-14as on Dec 31, 2016
-
EBITDA
-$21.37 M (USD)-14as on Dec 31, 2016
-
Total Equity Funding
$25.27 M (USD)
in 21 rounds
-
Latest Funding Round
$18.01 M (USD), Post-IPO
Nov 30, 2020
-
Investors
HHS
& 1 more
-
Employee Count
19
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of PLx Pharma
PLx Pharma is a publicly listed company on the LS with ticker symbol A2DMUN in Germany, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of PLx Pharma
Unlock access to complete
Unlock access to complete
Scientific Team
11 people
Leadership Team
5 people
Finance and Accounting
2 people
Cardiovascular Team
2 people
Unlock access to complete
Funding Insights of PLx Pharma
PLx Pharma has successfully raised a total of $25.27M across 21 strategic funding rounds. The most recent funding activity was a Post-IPO round of $18.01 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in PLx Pharma
PLx Pharma has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS and Aurus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for PLx Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PLx Pharma
Investment portfolio details for PLx Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PLx Pharma
Detailed financials for PLx Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Plx Pharma Comparisons
Peer comparison for PLx Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PLx Pharma
PLx Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ironwood Pharma, Lyndra, RedHill Biopharma, Alcresta and Seed, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
|
|
| Locked | Locked | Locked |
Innovates long-acting oral therapies to simplify patient medication regimens.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases
|
|
| Locked | Locked | Locked |
Enzyme-based products for gastrointestinal disorders are developed using immobilization technology.
|
|
| Locked | Locked | Locked |
Synbiotics are developed for simulating the gut microbiome.
|
|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
|
Detailed competitors of PLx Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Plx Pharma
Complete news archive for PLx Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PLx Pharma
PLx Pharma was founded in 2002 and raised its 1st funding round 6 years after it was founded.
PLx Pharma is headquartered in Sparta, United States.
Natasha Giordano is the current CEO of PLx Pharma.
PLx Pharma is a funded company, having raised a total of $25.27M across 21 funding rounds to date.
As of Dec 31, 2022, the latest employee count at PLx Pharma is 19.
Annual revenue of PLx Pharma is $778.66K as on Dec 31, 2017.
PLx Pharma was founded in 2002 in Sparta, United States, within the pharmaceutical sector. A patent-protected PLxGuard platform is utilized to target active ingredients to specific GI tract areas, supporting nonsteroidal anti-inflammatory and over-the-counter drugs. Operations focus on gastrointestinal treatments, including the development of Vazalore as a liquid-filled aspirin capsule for pain management. The companys domain is plxpharma.com.
PLx Pharma's top competitors include Ironwood Pharma, Ardelyx and RedHill Biopharma.
Yes, PLx Pharma is publicly traded on LS under the ticker symbol A2DMUN.
PLx Pharma has 2 investors. Key investors include HHS, and Aurus.
The ticker symbol of PLx Pharma is A2DMUN on LS.